Journal
AIDS RESEARCH AND THERAPY
Volume 8, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1742-6405-8-13
Keywords
-
Categories
Funding
- Canadian Institutes for Health Research
- National Institutes of Health
- Canadian Institutes of Health Research
- Health Canada
- Agouron Pharmaceuticals Inc
- Boehringer Ingelheim Pharmaceuticals Inc
- Bristol-Myers Squibb
- GlaxoSmithKline
- Merck Frosst Laboratories
- Abbott
- Argos Therapeutics
- Bioject Inc
- Boehringer Ingelheim
- BMS
- Gilead Sciences
- Hoffmann-La Roche
- Janssen-Ortho
- Merck Frosst
- Pfizer
- Schering
- Serono Inc
- TheraTechnologies
- Tibotec
- Trimeris
- NATIONAL INSTITUTE ON DRUG ABUSE [DP1DA026182] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Background: HIV/AIDS has orphaned 11.6 million children in sub-Saharan Africa. Expanded antiretroviral therapy (ART) use may reduce AIDS orphanhood by decreasing adult mortality and population-level HIV transmission. Methods: We modeled two scenarios to measure the impact of adult ART use on the incidence of orphanhood in 10 sub-Saharan African countries, from 2009 to 2020. Demographic model data inputs were obtained from cohort studies, UNAIDS, UN Population Division, WHO and the US Census Bureau. Results: Compared to current rates of ART uptake, universal ART access averted 4.37 million more AIDS orphans by year 2020, including 3.15 million maternal, 1.89 million paternal and 0.75 million double orphans. The number of AIDS orphans averted was highest in South Africa (901.71 thousand) and Nigeria (839.01 thousand), and lowest in Zimbabwe (86.96 thousand) and Cote d'Ivoire (109.12 thousand). Conclusion: Universal ART use may significantly reduce orphanhood in sub-Saharan Africa.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available